Title: |
Chinese Expert Consensus on Immunotherapy for Gynecological Malignant Tumors (2023 Edition) |
Edition: |
Original |
Classification: |
Experts consensus |
Field: |
Diagnosis and Treatment |
Countries and regions: |
China |
Guidelines users: |
Medical staff engaged in gynecological oncology work in clinical practice
|
Evidence classification method: |
This consensus adopts the following recommendation levels (Table 1), and for those without special instructions, the recommendation levels are all Class 2A.
Table 1 Recommendation Levels and Their Representative Significance
Recommendation level represents significance
Class 1 is based on advanced clinical research evidence, with highly consistent expert opinions
Class 2A is based on low-level clinical research evidence, with highly consistent expert opinions; Or based on advanced clinical research evidence, expert opinions are generally consistent
Category 2B is based on low-level clinical research evidence, and expert opinions are generally consistent
No matter what level of clinical research evidence is based on, there are obvious differences in expert opinions among the three categories |
Development unit: |
Onco-Endocrinology Special Committee of China Anti Cancer Association |
Registration time: |
2023-05-31 |
Registration number: |
PREPARE-2023CN373 |
Purpose of the guideline: |
The Onco-Endocrinology Special Committee of China Anti Cancer Association led the organization of experts in the field of cancer. Based on high-level evidence-based clinical evidence, experts jointly discussed and voted to form the "Chinese Expert Consensus on Immunotherapy for Gynecological Malignant Tumors (2023 Edition)" for reference by domestic peers, in order to further standardize the clinical practice of immunotherapy for gynecological malignant tumors.
|